Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Generating ectopic subcutaneous bone marrow by reconstitution of endochondral ossification

Hinako Notoh, Kanon Wada, Nobuaki Suzuki, Atsuo Suzuki, Shuichi Okamoto, Takeshi Kanematsu, Akira Katsumi, Testsuhito Kojima, Tadashi Matsushita, Shogo Tamura

Blood (2025) 146 (Supplement 1): 1403.

https://doi.org/10.1182/blood-2025-1403

Published: 2025

Journal Articles

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Steven Lentz, Aby Abraham, Cihan Ay, Anthony Chan, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Johnny Mahlangu, Tadashi Matsushita, Lize van Vulpen, Renchi Yang, Amalie Rhode Høgh Nielsen, Ilgiz Rakhmatullin, Pratima Chowdary

Blood (2025) 146 (Supplement 1): 537.

https://doi.org/10.1182/blood-2025-537

Published: 2025

Journal Articles

Use of emicizumab in patients with acquired hemophilia A: An interim safety analysis of a large-scale post‑marketing surveillance study

Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita

Blood (2025) 146 (Supplement 1): 4854.

https://doi.org/10.1182/blood-2025-4854

Published: 2025

Journal Articles

A FXIa-modified clot waveform analysis for estimation of factor VIII level and emicizumab concentration in hemophilia A

Oliver Königsbrügge, Atsuo Suzuki, Daniel Kraemmer, Nobuaki Suzuki, Ingrid Pabinger, Cihan Ay, Tadashi Matsushita

Blood (2025) 146 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2025-3065

Published: 2025

Journal Articles

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Keiji Nogami, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Akiko Ioka, Yoichi Murakami, Tomomi Shimura, Tadashi Matsushita

Blood (2025) 146 (Supplement 1): 303.

https://doi.org/10.1182/blood-2025-303

Published: 2025

Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen Tran, Chur-Woo You, Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet

Blood (2025) 145 (25): 2966–2977.

https://doi.org/10.1182/blood.2024027008

Published: 2025

Includes: Supplemental data

Journal Articles

Fourth Interim Analysis of the Hem Powr Study: A Post Hoc Analysis of Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Adolescent and Older Patients with Hemophilia a

Mark T Reding, María Teresa Alvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg

Blood (2024) 144 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2024-205121

Published: 2024

Journal Articles

Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Steven W. Pipe, Kaan Kavakli, Tadashi Matsushita, Huyen Tran, Bulent Zulfikar, Laurel Menapace, Marja Puurunen, Wenruo Hu, Yuqian Shen, Chanchala Kaddi, Vanessa Salinas

Blood (2024) 144 (Supplement 1): 128.

https://doi.org/10.1182/blood-2024-206946

Published: 2024

Journal Articles

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Azusa Nagao, Keiji Nogami, Nobuaki Suzuki, Chiai Nagae, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2588.

https://doi.org/10.1182/blood-2024-193535

Published: 2024

Journal Articles

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2024-193353

Published: 2024

Journal Articles

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Tadashi Matsushita, Pratima Chowdary, Atanas Mitkov Banchev, Kaan Kavakli, Johanna A. Kremer Hovinga, Jerzy Windyga, Víctor Jiménez-Yuste, Julien Bovet, Llenalia María García Fernández, Guy Young

Blood (2024) 144 (Supplement 1): 718.

https://doi.org/10.1182/blood-2024-198617

Published: 2024

Journal Articles

Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Amy D. Shapiro, Shashikant Apte, Ana Boban, Renée Brown Frandsen, Silvia Linari, Johnny Mahlangu, Camila Martins Mazini Tavares, Tadashi Matsushita, Salim Nekkal, Jameela Sathar, Anthony K C Chan

Blood (2024) 144 (Supplement 1): 715.

https://doi.org/10.1182/blood-2024-209759

Published: 2024

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Surgical Procedures and Hemostatic Outcome in Patients with Hemophilia Receiving Concizumab Prophylaxis during the Phase 3 explorer7 and explorer8 Trials

Anthony KC Chan, Chris Barnes, Mary Mathias, Silvia Linari, Francisco Jose Lopez Jaime, Lone Hvitfeldt Poulsen, Julien Bovet, Jan Odgaard-Jensen, Tadashi Matsushita

Blood (2023) 142 (Supplement 1): 30.

https://doi.org/10.1182/blood-2023-179739

Published: 2023

Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2023-173071

Published: 2023

Journal Articles

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Midori Shima, Masashi Taki, Rie Shirayama, Tadashi Matsushita, Yasuharu Nishida, Azusa Nagao, Yoshiyuki Ogawa, Kazuo Kawasugi

Blood (2022) 140 (Supplement 1): 11304–11305.

https://doi.org/10.1182/blood-2022-167449

Published: 2022

Journal Articles

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Gili Kenet, Ampaiwan Chuansumrit, Tadashi Matsushita, Guy Young, Vandana Yadav, Marek Zak, Christoph Male

Blood (2022) 140 (Supplement 1): 2726–2727.

https://doi.org/10.1182/blood-2022-162331

Published: 2022

Journal Articles

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Gili Kenet, Beatrice Nolan, Tadashi Matsushita, Guy Young, Ting Quan, Viridiana Cano, Christian Sussebach, Shauna Andersson, Baisong Mei, Marion Afonso, Kaan Kavakli

Blood (2022) 140 (Supplement 1): 7977–7978.

https://doi.org/10.1182/blood-2022-167169

Published: 2022

Journal Articles

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Mark T Reding, María Teresa Alvarez Román, Martin Sanabria, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg

Blood (2022) 140 (Supplement 1): 5612–5614.

https://doi.org/10.1182/blood-2022-169159

Published: 2022

Journal Articles

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Allison P. Wheeler, Gary Benson, Hermann Eichler, Sidsel Marie Tønder, Katarina Cepo, Victor Jimenez Yuste, Kaan Kavakli, Lily LL Wong, Tadashi Matsushita

Blood (2021) 138 (Supplement 1): 345.

https://doi.org/10.1182/blood-2021-148571

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Generating ectopic subcutaneous bone marrow by reconstitution of endochondral ossification

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Use of emicizumab in patients with acquired hemophilia A: An interim safety analysis of a large-scale post‑marketing surveillance study

A FXIa-modified clot waveform analysis for estimation of factor VIII level and emicizumab concentration in hemophilia A

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Fourth Interim Analysis of the Hem Powr Study: A Post Hoc Analysis of Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Adolescent and Older Patients with Hemophilia a

Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Surgical Procedures and Hemostatic Outcome in Patients with Hemophilia Receiving Concizumab Prophylaxis during the Phase 3 explorer7 and explorer8 Trials

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only